Cover Image
市場調查報告書

全球糖尿病視網膜病變市場各類型,管理規模,產業分析報告,各地區預測,潛在性用途,價格趨勢,競爭市場佔有率,未來預測

Diabetic Retinopathy Market Size, By Type, By Management, Industry Analysis Report, Regional Outlook Application Potential, Price Trends, Competitive Market Share & Forecast, 2017 - 2024

出版商 Global Market Insights Inc. 商品編碼 605740
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球糖尿病視網膜病變市場各類型,管理規模,產業分析報告,各地區預測,潛在性用途,價格趨勢,競爭市場佔有率,未來預測 Diabetic Retinopathy Market Size, By Type, By Management, Industry Analysis Report, Regional Outlook Application Potential, Price Trends, Competitive Market Share & Forecast, 2017 - 2024
出版日期: 2018年01月11日 內容資訊: 英文 90 Pages
簡介

本報告提供全球糖尿病視網膜病變市場相關調查,彙整市場概要和各市場區隔,各地區趨勢,及加入此市場的主要企業簡介等資料。

第1章 調查方法與範圍

第2章 摘要整理

第3章 產業趨勢

  • 產業市場區隔
  • 產業環境
  • 產業影響因素
    • 促進成長要素
    • 陷阱與課題
  • 成長可能性分析
  • 波特五力分析
  • 競爭環境
  • PESTEL分析
  • 流行病學
  • 開發平台

第4章 各類型市場

  • 市場佔有率
  • 增生性
  • 非增生性

第5章 各管理市場

  • 市場佔有率
  • 抗VEGF治療
  • 眼內類固醇注射
  • 雷射手術
  • 玻璃體切除術

第6章 各地區市場

  • 各地區市場佔有率
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第7章 企業簡介

  • Aerpio Pharmaceuticals
  • Alimera Sciences, Inc
  • Allergan PLC (Actavis PLC)
  • Ampio Pharmaceuticals, Inc.
  • Bayer AG
  • BCN Peptides S.A.
  • Genentech, Inc.
  • 興和株式會社
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Sirnaomics, Inc.
  • ThromboGenics ?7.12.1. Business overview

圖表

目錄
Product Code: 486

Title:
Diabetic Retinopathy Market Size, By Type (Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy), By Management (Anti VEGF Drug, Intra-ocular Steroid Injections, Laser Surgeries, Vitrectomy), Industry Analysis Report, Regional Outlook (U.S., Canada, UK, Germany, Japan, China, Brazil and South Africa) Application Potential, Price Trends, Competitive Market Share & Forecast, 2017 - 2024.

Diabetic Retinopathy Market will reach USD 11 billion by 2024; according to a new research report.

Rising prevalence of diabetes coupled with increasing geriatric population worldwide will drive diabetic retinopathy market over the forecast timeframe. Increasing R&D efforts to develop efficient and affordable solutions to treat diabetic retinopathy as well as growing awareness about diabetes associated vision loss will fuel market growth.

Technological advancements in eye disease diagnosis pre-occurrence of blindness coupled with rising adoption of unhealthy diet and sedentary lifestyle fueling disease such as diabetes will favor diabetic retinopathy market growth.

Favorable reimbursement policies such as coverage for annual retinopathy screening of diabetic population in Canada along with programs such as 'Action for Diabetes' and diabetic eye screening will propel industry growth. Growing demand for advanced treatment, rising healthcare expenditure coupled with public and private players initiatives to reduce diabetic retinopathy prevalence by creating awareness will favor market growth.

Factors such as non-compliance to treatment, less or no awareness about diabetes leading to vision impairment as well as undiagnosed diabetes for prolonged period will fuel industry growth. However, scarcity of trained ophthalmologists and extensive time required for approval of drugs for diabetic retinopathy treatment might impede market growth.

Non-proliferative diabetic retinopathy market will witness lucrative growth over the forecast period. Rising incidences of diabetes among elderly as well as youth population coupled with prolonged high blood glucose levels will drive non-proliferative diabetic retinopathy market over the forecast period.

Growing incidences of diabetic macular edema (DME) coupled with technological advancements will drive intraocular steroid injection market over the coming years. Intraocular steroid injection reduces leakage of fluid in retina thus resulting in enhanced vision will further propel industry growth.

U.S. diabetic retinopathy market held largest market share in 2016 and is estimated to follow similar trend over the forecast period due to the presence of geriatric patient pool, rising healthcare expenditure and presence of several market players.

UK diabetic retinopathy market will grow considerable over the forecast timeframe owing to high technological adoption, rising research activities focusing on studying visual impairment due to diabetes and growing prevalence of diabetic retinopathy in the country.

High geriatric population base and growing adoption of unhealthy lifestyle including consumption of high sugar and fat content food coupled with lack of physical exercise leading to rising incidences of diabetes will drive Chinese diabetic retinopathy market.

Some of the industry players are Bayer AG, Genentech, Novartis, Sirnaomics, Regeneron Pharmaceuticals, Kowa Company, BCN Peptides, Allergan, Aerpio Pharmaceuticals, Ampio Pharmaceuticals, and Alimera Sciences.

Major industry players are focusing on research activities to develop innovative products to treat diabetic retinopathy. They are also emphasizing on partnership and collaboration to strengthen their existing product portfolio.

Table of Contents

Chapter 1. Methodology & Scope

  • 1.1. Methodology
    • 1.1.1. Initial data exploration
    • 1.1.2. Statistical model and forecast
    • 1.1.3. Industry insights and validation
    • 1.1.4. Market definition and forecast parameters
  • 1.2. Data Sources
    • 1.2.1. Secondary
    • 1.2.2. Primary

Chapter 2. Executive Summary

  • 2.1. Diabetic retinopathy industry 360 degree synopsis, 2012 - 2024
    • 2.1.1. Business trends
    • 2.1.2. Type trends
    • 2.1.3. Management trends
    • 2.1.4. Regional trends

Chapter 3. Diabetic Retinopathy Industry Insights

  • 3.1. Industry segmentation
  • 3.2. Industry landscape, 2012 - 2024
  • 3.3. Industry impact forces
    • 3.3.1. Growth drivers
    • 3.3.1.1. Growing geriatric population
    • 3.3.1.2. High prevalence of diabetes
    • 3.3.1.3. Increasing occurrence of blindness due to diabetes
    • 3.3.1.4. Large patient population
    • 3.3.2. Industry pitfalls & challenges
    • 3.3.2.1. Dearth of trained ophthalmologists
    • 3.3.2.2. Extensive time for approval of drugs
  • 3.4. Growth potential analysis
    • 3.4.1. By type
    • 3.4.2. By management
  • 3.5. Porter's analysis
  • 3.6. Competitive landscape, 2016
    • 3.6.1. Strategy dashboard
  • 3.7. PESTEL analysis
  • 3.8. Diabetic retinopathy epidemiology
    • 3.8.1. U.S.
    • 3.8.2. Germany
    • 3.8.3. UK
    • 3.8.4. China
  • 3.9. Diabetic retinopathy pipeline

Chapter 4. Diabetic Retinopathy Market, By Type

  • 4.1. Global diabetic retinopathy market share, by type, 2016 & 2024
  • 4.2. Proliferative
    • 4.2.1. Market estimates and forecast, by region, 2012 - 2024
  • 4.3. Non-Proliferative
    • 4.3.1. Market estimates and forecast, by region, 2012 - 2024

Chapter 5. Diabetic Retinopathy Market, By Management

  • 5.1. Global diabetic retinopathy market share, by management, 2016 & 2024
  • 5.2. Anti-VEGF therapy
    • 5.2.1. Market estimates and forecast, by region, 2012 - 2024
  • 5.3. Intraocular steroid injection
    • 5.3.1. Market estimates and forecast, by region, 2012 - 2024
  • 5.4. Laser surgery
    • 5.4.1. Market estimates and forecast, by region, 2012 - 2024
  • 5.5. Vitrectomy
    • 5.5.1. Market estimates and forecast, by region, 2012 - 2024

Chapter 6. Diabetic Retinopathy Market, By Region

  • 6.1. Diabetic retinopathy market share, by region, 2016 & 2024
  • 6.2. North America
    • 6.2.1. Market estimates and forecast, by country, 2012 - 2024
    • 6.2.2. Market estimates and forecast, by type, 2012 - 2024
    • 6.2.3. Market estimates and forecast, by management, 2012 - 2024
    • 6.2.4. U.S.
    • 6.2.4.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.2.4.2. Market estimates and forecast, by management, 2012 - 2024
    • 6.2.5. Canada
    • 6.2.5.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.2.5.2. Market estimates and forecast, by management, 2012 - 2024
  • 6.3. Europe
    • 6.3.1. Market estimates and forecast, by country, 2012 - 2024
    • 6.3.2. Market estimates and forecast, by type, 2012 - 2024
    • 6.3.3. Market estimates and forecast, by management, 2012 - 2024
    • 6.3.4. Germany
    • 6.3.4.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.3.4.2. Market estimates and forecast, by management, 2012 - 2024
    • 6.3.5. UK
    • 6.3.5.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.3.5.2. Market estimates and forecast, by management, 2012 - 2024
  • 6.4. Asia Pacific
    • 6.4.1. Market estimates and forecast, by country, 2012 - 2024
    • 6.4.2. Market estimates and forecast, by type, 2012 - 2024
    • 6.4.3. Market estimates and forecast, by management, 2012 - 2024
    • 6.4.4. Japan
    • 6.4.4.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.4.4.2. Market estimates and forecast, by management, 2012 - 2024
    • 6.4.5. China
    • 6.4.5.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.4.5.2. Market estimates and forecast, by management, 2012 - 2024
  • 6.5. Latin America
    • 6.5.1. Market estimates and forecast, by country, 2012 - 2024
    • 6.5.2. Market estimates and forecast, by type, 2012 - 2024
    • 6.5.3. Market estimates and forecast, by management, 2012 - 2024
    • 6.5.4. Brazil
    • 6.5.4.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.5.4.2. Market estimates and forecast, by management, 2012 - 2024
  • 6.6. Middle East & Africa
    • 6.6.1. Market estimates and forecast, by country, 2012 - 2024
    • 6.6.2. Market estimates and forecast, by type, 2012 - 2024
    • 6.6.3. Market estimates and forecast, by management, 2012 - 2024
    • 6.6.4. South Africa
    • 6.6.4.1. Market estimates and forecast, by type, 2012 - 2024
    • 6.6.4.2. Market estimates and forecast, by management, 2012 - 2024

Chapter 7. Company Profiles

  • 7.1. Aerpio Pharmaceuticals
    • 7.1.1. Business overview
    • 7.1.2. Financial data
    • 7.1.3. Product landscape
    • 7.1.4. Strategic outlook
    • 7.1.5. SWOT analysis
  • 7.2. Alimera Sciences, Inc
    • 7.2.1. Business overview
    • 7.2.2. Financial data
    • 7.2.3. Product landscape
    • 7.2.4. Strategic outlook
    • 7.2.5. SWOT analysis
  • 7.3. Allergan PLC (Actavis PLC)
    • 7.3.1. Business overview
    • 7.3.2. Financial data
    • 7.3.3. Product landscape
    • 7.3.4. Strategic outlook
    • 7.3.5. SWOT analysis
  • 7.4. Ampio Pharmaceuticals, Inc.
    • 7.4.1. Business overview
    • 7.4.2. Financial data
    • 7.4.3. Product landscape
    • 7.4.4. Strategic outlook
    • 7.4.5. SWOT analysis
  • 7.5. Bayer AG
    • 7.5.1. Business overview
    • 7.5.2. Financial data
    • 7.5.3. Product landscape
    • 7.5.4. Strategic outlook
    • 7.5.5. SWOT analysis
  • 7.6. BCN Peptides S.A.
    • 7.6.1. Business overview
    • 7.6.2. Financial data
    • 7.6.3. Product landscape
    • 7.6.4. Strategic outlook
    • 7.6.5. SWOT analysis
  • 7.7. Genentech, Inc.
    • 7.7.1. Business overview
    • 7.7.2. Financial data
    • 7.7.3. Product landscape
    • 7.7.4. Strategic outlook
    • 7.7.5. SWOT analysis
  • 7.8. Kowa Company Ltd.
    • 7.8.1. Business overview
    • 7.8.2. Financial data
    • 7.8.3. Product landscape
    • 7.8.4. Strategic outlook
    • 7.8.5. SWOT analysis
  • 7.9. Novartis AG
    • 7.9.1. Business overview
    • 7.9.2. Financial data
    • 7.9.3. Product landscape
    • 7.9.4. Strategic outlook
    • 7.9.5. SWOT analysis
  • 7.10. Regeneron Pharmaceuticals, Inc.
    • 7.10.1. Business overview
    • 7.10.2. Financial data
    • 7.10.3. Product landscape
    • 7.10.4. Strategic outlook
    • 7.10.5. SWOT analysis
  • 7.11. Sirnaomics, Inc.
    • 7.11.1. Business overview
    • 7.11.2. Financial data
    • 7.11.3. Product landscape
    • 7.11.4. Strategic outlook
    • 7.11.5. SWOT analysis
  • 7.12. ThromboGenics
    • 7.12.1. Business overview
    • 7.12.2. Financial data
    • 7.12.3. Product landscape
    • 7.12.4. Strategic outlook
    • 7.12.5. SWOT analysis

Data Tables

  • TABLE 1. Diabetic retinopathy industry 360 degree synopsis, 2012 - 2024
  • TABLE 2. Global diabetic retinopathy market, 2012-2016 (USD Million)
  • TABLE 3. Global diabetic retinopathy market, 2017-2024 (USD Million)
  • TABLE 4. Global diabetic retinopathy market, by type, 2012 - 2016 (USD Million)
  • TABLE 5. Global diabetic retinopathy market, by type, 2017 - 2024 (USD Million)
  • TABLE 6. Global diabetic retinopathy market, by management, 2012-2016 (USD Million)
  • TABLE 7. Global diabetic retinopathy market, by management, 2017-2024 (USD Million)
  • TABLE 8. Global diabetic retinopathy market, by region, 2012-2016 (USD Million)
  • TABLE 9. Global diabetic retinopathy market, by region, 2017-2024 (USD Million)
  • TABLE 10. Industry impact forces
  • TABLE 11. Lifetime prevalence of diagnosed diabetes mellitus in men(Germany)
  • TABLE 12. Prevalence of different diabetic retinopathy types
  • TABLE 13. Prevalence of diabetic retinopathy in patients with type II diabetes in Europe
  • TABLE 14. Prevalence of diabetes in the adult population across the UK in 2014
  • TABLE 15. Diabetic retinopathy pipeline
  • TABLE 16. Proliferative market size, by region, 2012-2024 (USD Million)
  • TABLE 17. Non-proliferative market size, by region, 2012-2024 (USD Million)
  • TABLE 18. Anti-VEGF therapy testing market size, by region, 2012-2024 (USD Million)
  • TABLE 19. Intraocular steroid injection market size, by region, 2012-2024 (USD Million)
  • TABLE 20. Laser surgery market size, by region, 2012-2024 (USD Million)
  • TABLE 21. Vitrectomy market size, by region, 2012-2024 (USD Million)
  • TABLE 22. North America diabetic retinopathy market size, by country, 2012 - 2024 (USD Million)
  • TABLE 23. North America diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 24. North America diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 25. U.S. diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 26. U.S. diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 27. Canada diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 28. Canada diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 29. Prevalence of diabetic retinopathy among patients with type II diabetes in European countries
  • TABLE 30. Europe diabetic retinopathy market size, by country, 2012 - 2024 (USD Million)
  • TABLE 31. Europe diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 32. Europe diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 33. UK diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 34. UK diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 35. Germany diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 36. Germany diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 37. Asia Pacific diabetic retinopathy market size, by country, 2012 - 2024 (USD Million)
  • TABLE 38. Asia Pacific diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 39. Asia Pacific diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 40. Japan diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 41. Japan diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 42. China diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 43. China diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 44. Latin America diabetic retinopathy market size, by country, 2012 - 2024 (USD Million)
  • TABLE 45. Latin America diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 46. Latin America diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 47. Brazil diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 48. Brazil diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 49. MEA diabetic retinopathy market size, by country, 2012 - 2024 (USD Million)
  • TABLE 50. MEA diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 51. MEA diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)
  • TABLE 52. South Africa diabetic retinopathy market size, by type, 2012 - 2024 (USD Million)
  • TABLE 53. South Africa diabetic retinopathy market size, by management, 2012 - 2024 (USD Million)

Charts & Figures

  • FIG. 1. Industry segmentation
  • FIG. 2. Global diabetic retinopathy market, 2013- 2024 (USD Million)
  • FIG. 3. Growth potential analysis, by type
  • FIG. 4. Growth potential analysis, by management
  • FIG. 5. Porter's analysis
  • FIG. 6. PESTEL analysis
  • FIG. 7. Strategy dashboard
  • FIG. 8. Diabetic retinopathy market share, by type, 2016 & 2024
  • FIG. 9. Diabetic retinopathy market share, by management, 2016 & 2024
  • FIG. 10. Diabetic retinopathy market share, by region, 2016 & 2024
Back to Top